BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$61.93 USD
+1.62 (2.69%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $61.92 -0.01 (-0.02%) 7:48 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Fundamental Charts
About Dividend Yield (TTM)
BioMarin Pharmaceutical Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
BMRN 61.93 +1.62(2.69%)
Will BMRN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMRN
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
Other News for BMRN
BMRN Makes Bullish Cross Above Critical Moving Average
UBS Updates Its Analyst Rating and Target Price for BMRN | BMRN Stock News
UBS Adjusts Price Target for BioMarin (BMRN) to $114
BioMarin price target raised by $1 at UBS
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401